rivaroxaban and Sleep-Apnea-Syndromes

Patients with sleep-disordered breathing exhibit intermittent hypoxia that causes increased oxidative stress, accelerates atherosclerosis, and pulmonary hypertension, resulting in life-threatening arrhythmias and congestive heart failure. Hypoxic stress caused by intermittent hypoxia might be involved in the pathophysiology of many cardiovascular diseases, especially those involving atrial fibrillation, for which anti-coagulant therapy may be recommended. In this study, the inhibition of proteinase-activated receptor (PAR) 1/2 significantly reduced oxidative stress and fibrosis while suppressing the activation of MAPK or Smad pathways and the gene expression of molecules responsible for the pathways in the myocardium, consequently attenuating hypoxia-mediated cardiomyocyte hypertrophy. These findings suggest that the inhibition of PAR 1/2 could be a novel potential treatment option to prevent cardiac remodeling in patients with sleep apnea syndrome and atrial fibrillation or chronic thromboembolic pulmonary hypertension.

Topics: Animals; Atherosclerosis; Atrial Fibrillation; Cardiovascular Diseases; Disease Models, Animal; Humans; Hypertension, Pulmonary; Hypoxia; Mice, Inbred C57BL; Molecular Targeted Therapy; Oxidative Stress; Rats; Receptor, PAR-1; Receptor, PAR-2; Rivaroxaban; Sleep Apnea Syndromes; Ventricular Remodeling